Florida Marketer Genetic Testing Kickbacks: Payment Only After Medicare Reimbursement

A Florida marketer’s genetic testing kickbacks helped drive a healthcare scheme that caused more than $4.8 million in Medicare losses, according to the Justice Department’s account of his guilty plea. The arrangement paid him for cancer genetic screening tests that Medicare reimbursed, while contracts called the money expenses. For someone who handled the commissions or invoices, the difference between those descriptions is the heart of the case.

In its July 16, 2025 announcement, the department said the Palm Beach Shores marketer pleaded guilty to conspiring to commit health care fraud and to violate the federal Anti-Kickback Statute. The plea announcement described how recruitment, mailed testing kits and laboratory claims generated payments back to the person bringing in the beneficiaries.

From a Call Center to a Paid Test

The Justice Department’s account of the guilty plea placed the scheme between February and September 2019. The marketer used call centers that employed deceptive telemarketing to obtain Medicare beneficiaries’ personal and medical information. He and other participants then arranged for cancer genetic screening kits to be sent to those beneficiaries.

Once beneficiaries completed the kits, the kits went to a testing laboratory. The laboratory submitted claims to Medicare. The plea announcement described the tests as medically unnecessary and obtained through bribes and kickbacks. Beneficiaries were deceived into giving up personal and medical information, and Medicare paid for tests they did not need.

That sequence matters to an insider because the work was divided. The caller obtained the information. Other participants arranged the kits. The laboratory submitted the claim. The marketer’s compensation depended on what happened at the payment end of the chain. A person working on one part could see a recruitment or testing operation while the money connecting those parts appeared somewhere else.

Payment Only After Medicare Reimbursement

The Justice Department’s plea announcement said the marketer received more than $1,200 for each cancer genetic screening test that resulted in Medicare reimbursement. His payments depended solely on the number of tests Medicare reimbursed.

Recruiting a beneficiary and getting a kit completed moved the transaction along, but Medicare reimbursement was what triggered the marketer’s compensation. The federal program’s payment was therefore part of the referral arrangement itself.

Someone working on commissions could recognize that condition without working at a laboratory bench. The relevant question inside the business was which tests Medicare had paid. A contract describing expenses concealed that connection. The compensation formula exposed it.

Contracts Called the Kickbacks Expenses

According to the Justice Department’s guilty-plea announcement, the marketer entered contracts with other participants that falsely labeled bribes and kickbacks as expenses. They then created false invoices to disguise why the money was changing hands.

The paperwork did more than omit an uncomfortable description. It supplied an alternative explanation for payments that the department said were based solely on reimbursed tests. The contracts described one reason to pay. The arrangement used another.

That is why an invoice can be as revealing as the referral itself. In this case, the document presented as an expense record was part of the concealment. Reading it alongside the payment condition changes its meaning: the question becomes which paid tests generated the money shown as expenses.

Why Medicare Needs a Medical Reason for a Genetic Test

Medicare’s diagnostic-testing rules require the treating practitioner to use the test in managing the patient’s medical problem and document why it is needed. The laboratory keeps the information it receives and records showing that its claim reflects it accurately.

That division gives this case a clinical question alongside the payment question. The guilty-plea announcement described medically unnecessary cancer genetic screening. A completed kit explained how a sample reached the laboratory. The medical record had to explain why the patient needed the test. Recruitment information and a clinical reason serve different purposes, even when both travel toward the same claim.

The laboratory literature has long treated the requisition as part of that connection. In Model Plan Helps Laboratories Fight Fraud, published in Laboratory Medicine in 1997, the discussion of the government’s voluntary compliance model described uniform requisition forms with space for the physician to document each test’s medical necessity through a diagnosis code. The model also recommended retaining and analyzing test-use data, as well as policies for creating and retaining records. The forms preserve the reason for individual tests. The test-use records show the laboratory’s pattern of work.

A clinical record explains the testing decision. An invoice explains a transfer of money. Here, the plea announcement described unnecessary tests on the clinical side and false expense paperwork on the payment side. Reading only the invoice would miss the testing. Reading only the claim would miss what the recruiter was paid.

What Evidence Is Needed to Prove Fraud?

For reimbursement-based genetic testing kickbacks, the contracts, invoices and reimbursement records connect what the parties said they were paying for with what actually triggered payment. The guilty-plea announcement identified both the payment formula and the false documents used to conceal it.

Those records answer different questions. The contract gives the stated reason for the arrangement. The invoice gives the reason presented for a particular payment. Reimbursement records show which tests Medicare paid. Comparing them can reveal whether an expense description follows a reimbursed-test count instead of the activity the contract describes.

Your knowledge of how that comparison worked inside the business can give the documents their meaning. If you handled an invoice or a commission calculation, you may know why a payment was approved and what information went into it. Our whistleblower experts work with you on that connection between the company’s explanation, the testing claims and the money.

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.

You Know What Triggered the Commission

If you saw expenses calculated from paid genetic tests, talk with our whistleblower experts about the arrangement behind the invoices. We develop the case with you and bring in laboratory fraud whistleblower lawyers who understand genetic-testing referrals and Medicare claims. We stay beside you through the case, keeping what you know about the payment arrangement at its center.